FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 08:26:14 2024-07-11 am EDT | ||
| 1.6 EUR | -2.44% |
|
| Current month | -15.03% | ||
| 1 month | -8.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.6 | -2.44% |
| 24-07-10 | 1.64 | -4.09% |
| 24-07-09 | 1.71 | -3.93% |
| 24-07-08 | 1.78 | -7.29% |
| 24-07-05 | 1.92 | -4.95% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 08:26 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2ECA |
| ISIN | DE000GG2ECA9 |
| Date issued | 2024-01-11 |
| Strike | 589.9 $ |
| Maturity | Unlimited |
| Parity | 57.4 : 1 |
| Emission price | 4.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.64 € |
|---|---|
| Lowest since issue | 1.59 € |
| Spread | 0.02 € |
| Spread % | 1.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
491.6
USD
Average target price
473.1
USD
Spread / Average Target
-3.77%
- Stock Market
- Certificates
- Certificat
